Abstract: The present disclosure provides methods for detecting macro-heteroplasmy and/or micro-heteroplasmy in mitochondrial DNA. The methods can include detecting or monitoring the presence of heteroplasmy, and/or identifying a threshold level of heteroplasmy. In addition, the methods can be used for diagnosing a mitochondrial related disease or disorder, as well as for monitoring the efficacy of a therapy affecting mitochondrial DNA (mtDNA) in a subject having or suspected of having heteroplasmy.

Abstract: The present disclosure provides methods for detecting macro-heteroplasmy and/or micro-heteroplasmy in mitochondrial DNA. The methods can include detecting or monitoring the presence of heteroplasmy, and/or identifying a threshold level of heteroplasmy. In addition, the methods can be used for diagnosing a mitochondrial related disease or disorder, as well as for monitoring the efficacy of a therapy affecting mitochondrial DNA (mtDNA) in a subject having or suspected of having heteroplasmy.

Abstract: The present disclosure provides methods and compositions for generating mitochondria replaced lymphoid cells, such as T cells, that involves incubating lymphoid cells that have not undergone a procedure to reduce or deplete endogenous mitochondria with isolated exogenous mitochondria and an effective amount of mammalian target of rapamycin (mTOR) inhibitor. In addition, the present disclosure also provides methods of treating an immunological deficiency associated with heteroplasmic immune cells, as well as methods for ameliorating a symptom of mitochondrial complex III deficiency, that involve administering the mitochondria replaced lymphoid cells.

Abstract: It is solved by the rod-shaped tubular cell structure maintaining support device for cultivating a tubular cell structure including a hollow portion inside for a predetermined period of time while maintaining the hollow portion, the tubular cell structure maintaining support device including an outer diameter insertable into the hollow portion of the cell structure, and when inserted into the hollow portion, capable of allowing the tubular cell structure maintaining support device to adhere to an inner surface of the cell structure, and a penetration conduit including openings at both ends of the tubular cell structure maintaining support device, and penetrating between the openings, wherein the tubular cell structure maintaining support device has an oxygen permeable structure from the penetration conduit to an outer surface of the tubular cell structure maintaining support device.

Abstract: The present disclosure provides methods and compositions for producing mitochondria replaced T cells from exhausted T cells, that involves reducing exhausted T cells mitochondrial DNA (mtDNA) and incubating with isolated exogenous mitochondria for a sufficient period of time to generate mitochondria replaced T cells in which expression of at least one exhaustion marker is altered by at least 5%, at least 10%, 20% (e.g., at least 1.25 fold), at least 30%, at least 40%, at least 50%, at least 60%, or more, wherein the mitochondria replaced T cells have improved effector function relative to the exhausted T cells. In addition, the present disclosure also provides methods of treating or ameliorating an age-related disease (e.g., cancer or an autoimmune disease), as well as methods for ameliorating a symptom of a chronic infection (e.g., a chronic viral infection), that involve administering the mitochondria replaced T cells.

Abstract: An object of the present invention is to provide an excellent treatment agent for a lysosomal storage disease. According to the present invention, there is provided a treatment agent for a lysosomal storage disease including a cell structure which includes a plurality of biocompatible polymer blocks and a plurality of cells of at least one type and in which at least one of the polymer blocks is disposed in gaps between the plurality of cells.

Abstract: There is provided a bioabsorbable peptide tissue occluding agent that can be applied to large mammals including humans, the peptide tissue occluding agent being obtained by artificial synthesis to avoid concerns of infection by viruses and the like. The tissue occluding agent contains a peptide, wherein the peptide is an amphiphilic peptide having 8-200 amino acid residues with the hydrophilic amino acids and hydrophobic amino acids alternately bonded, and is a self-assembling peptide exhibiting a ?-structure in aqueous solution in the presence of physiological pH and/or a cation.

Abstract: There is provided a bioabsorbable peptide tissue occluding agent that can be applied to large mammals including humans, the peptide tissue occluding agent being obtained by artificial synthesis to avoid concerns of infection by viruses and the like. The tissue occluding agent contains a peptide, wherein the peptide is an amphiphilic peptide having 8-200 amino acid residues with the hydrophilic amino acids and hydrophobic amino acids alternately bonded, and is a self-assembling peptide exhibiting a ?-structure in aqueous solution in the presence of physiological pH and/or a cation.

Abstract: Provided are a B-cell antibody receptor (BAR), a BAR-T cell and others which are effective for the treatment of diseases associated with antibodies produced in the bodies of patients. The B-cell antibody receptor (BAR) according to the present invention comprises (a) an antibody binding domain, (b) a transmembrane domain, (c) an intracellular domain of a costimulating factor and (d) an intracellular domain of an activated receptor which are linked together.

Abstract: There is provided a bioabsorbable peptide tissue occluding agent that can be applied to large mammals including humans, the peptide tissue occluding agent being obtained by artificial synthesis to avoid concerns of infection by viruses and the like. The tissue occluding agent contains a peptide, wherein the peptide is an amphiphilic peptide having 8-200 amino acid residues with the hydrophilic amino acids and hydrophobic amino acids alternately bonded, and is a self-assembling peptide exhibiting a ?-structure in aqueous solution in the presence of physiological pH and/or a cation.

Abstract: The present disclosure provides methods for detecting macro-heteroplasmy and/or micro-heteroplasmy in mitochondrial DNA. The methods can include detecting or monitoring the presence of heteroplasmy, and/or identifying a threshold level of heteroplasmy. In addition, the methods can be used for diagnosing a mitochondrial related disease or disorder, as well as for monitoring the efficacy of a therapy affecting mitochondrial DNA (mtDNA) in a subject having or suspected of having heteroplasmy.

Abstract: It is solved by the rod-shaped tubular cell structure maintaining support device for cultivating a tubular cell structure including a hollow portion inside for a predetermined period of time while maintaining the hollow portion, the tubular cell structure maintaining support device including an outer diameter insertable into the hollow portion of the cell structure, and when inserted into the hollow portion, capable of allowing the tubular cell structure maintaining support device to adhere to an inner surface of the cell structure, and a penetration conduit including openings at both ends of the tubular cell structure maintaining support device, and penetrating between the openings, wherein the tubular cell structure maintaining support device has an oxygen permeable structure from the penetration conduit to an outer surface of the tubular cell structure maintaining support device.

Abstract: There is provided a bioabsorbable peptide tissue occluding agent that can be applied to large mammals including humans, the peptide tissue occluding agent being obtained by artificial synthesis to avoid concerns of infection by viruses and the like. The tissue occluding agent contains a peptide, wherein the peptide is an amphiphilic peptide having 8-200 amino acid residues with the hydrophilic amino acids and hydrophobic amino acids alternately bonded, and is a self-assembling peptide exhibiting a ?-structure in aqueous solution in the presence of physiological pH and/or a cation.

Abstract: An object of the present invention is to provide an excellent treatment agent for a lysosomal storage disease. According to the present invention, there is provided a treatment agent for a lysosomal storage disease including a cell structure which includes a plurality of biocompatible polymer blocks and a plurality of cells of at least one type and in which at least one of the polymer blocks is disposed in gaps between the plurality of cells.

Abstract: There is provided a bioabsorbable peptide tissue occluding agent that can be applied to large mammals including humans, the peptide tissue occluding agent being obtained by artificial synthesis to avoid concerns of infection by viruses and the like. The tissue occluding agent contains a peptide, wherein the peptide is an amphiphilic peptide having 8-200 amino acid residues with the hydrophilic amino acids and hydrophobic amino acids alternately bonded, and is a self-assembling peptide exhibiting a ?-structure in aqueous solution in the presence of physiological pH and/or a cation.

Abstract: There is provided a bioabsorbable peptide tissue occluding agent that can be applied to large mammals including humans, the peptide tissue occluding agent being obtained by artificial synthesis to avoid concerns of infection by viruses and the like. The tissue occluding agent contains a peptide, wherein the peptide is an amphiphilic peptide having 8-200 amino acid residues with the hydrophilic amino acids and hydrophobic amino acids alternately bonded, and is a self-assembling peptide exhibiting a ?-structure in aqueous solution in the presence of physiological pH and/or a cation.

Abstract: The present invention provides methods and compositions for generation of mitochondria replaced cells (MirC), and therapeutic methods for using such compositions for treating a subject having an age-related disease or syndrome, mitochondrial disease or disorder, or otherwise in need of mitochondrial replacement. Also provided are methods and compositions for producing a recipient cell having a mitochondrial disease or disorder, as well as methods and compositions for producing or enhancing production of an inducible pluripotent stem cell (iPSC). In addition, methods and compositions to enhance mitochondrial transfer are also included.

Abstract: An object of the present invention is to provide a method of manufacturing a large number of uniform cell structures for a short period of time. According to the present invention, provided is a method of manufacturing a cell structure, including: a step of adding a mixture of biocompatible macromolecular blocks, cells, and a liquid medium to a first culture container having a culture surface on which the plurality of recessed portions are formed and a side wall part standing on an outer periphery of the culture surface such that a liquid surface of the mixture is over the culture surface; a step of allowing a first culture container to stand and forming a cell structure in the recessed portion; and a step of stirring and culturing a content of the first culture container in a second culture container including stirring means.

Abstract: There is provided a bioabsorbable peptide tissue occluding agent that can be applied to large mammals including humans, the peptide tissue occluding agent being obtained by artificial synthesis to avoid concerns of infection by viruses and the like. The tissue occluding agent contains a peptide, wherein the peptide is an amphiphilic peptide having 8-200 amino acid residues with the hydrophilic amino acids and hydrophobic amino acids alternately bonded, and is a self-assembling peptide exhibiting a ?-structure in aqueous solution in the presence of physiological pH and/or a cation.

Abstract: There is provided a bioabsorbable peptide tissue occluding agent that can be applied to large mammals including humans, the peptide tissue occluding agent being obtained by artificial synthesis to avoid concerns of infection by viruses and the like. The tissue occluding agent contains a peptide, wherein the peptide is an amphiphilic peptide having 8-200 amino acid residues with the hydrophilic amino acids and hydrophobic amino acids alternately bonded, and is a self-assembling peptide exhibiting a ?-structure in aqueous solution in the presence of physiological pH and/or a cation.